The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for OrbiMed Asia IV Mauritius FVCI Ltd
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
BSE has received a disclosure under Regulation 29(2) of SEBI's Substantial Acquisition of Shares & Takeovers (SAST) Regulations, 2011, filed by OrbiMed Asia IV Mauritius FVCI Ltd in relation to Marksans Pharma Ltd. Regulation 29(2) disclosures are triggered when a shareholder's voting rights in a company change due to buying or selling shares. The actual filing details (number of shares, transaction type, percentage change) could not be accessed as the source page returned an error and was unavailable for review. Without the underlying document, the direction (acquisition or disposal) and magnitude of the change cannot be confirmed.
OrbiMed Asia IV is a known foreign investor in Marksans Pharma, so this disclosure relates to a change in institutional shareholding. Shareholders should look for the full disclosure on the BSE corporate announcements page to determine whether this is a buy or sell and assess any impact on stock price or holdings.